Sugi Predict

Sugi Predict / Compounds / SCHEMBL2984292

SCHEMBL2984292

SCHEMBL2984292

COC(=O)C(N=Cc1ccccc1)c1ccccc1

nearest known ligand 0.67

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 5/20 0.51
▸ MIF P14174 6/20 0.50
▸ MEN1 O00255 4/20 0.44
▸ CA1 P00915 1/20 0.44
▸ CA2 P00918 1/20 0.44
▸ MAPT P10636 1/20 0.40
▸ HPGD P15428 1/20 0.40
▸ PTGS1 P23219 1/20 0.40
▸ PTGS2 P35354 1/20 0.40
▸ ALDH1A1 P00352 1/20 0.40
▸ LMNA P02545 1/20 0.40
▸ FAAH O00519 1/20 0.40
▸ NPC1 O15118 1/20 0.40
▸ RAB9A P51151 1/20 0.40
▸ GAA P10253 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9734293 1.00 KMT2A (0.51) KMT2AMIFMEN1CA1CA2
SCHEMBL2984290 1.00 KMT2A (0.51) KMT2AMIFMEN1CA1CA2
SCHEMBL10855787 1.00 KMT2A (0.51) KMT2AMIFMEN1CA1CA2
SCHEMBL10858254 0.91 MIF (0.59) KMT2AMIFCA1CA2LMNA
SCHEMBL10858256 0.91 MIF (0.59) KMT2AMIFCA1CA2LMNA
SCHEMBL7267672 0.90 MIF (0.48) KMT2AMIFMEN1MAPTNPC1
SCHEMBL7267668 0.90 MIF (0.48) KMT2AMIFMEN1MAPTNPC1
SCHEMBL7267667 0.90 MIF (0.48) KMT2AMIFMEN1MAPTNPC1
SCHEMBL13505156 0.84 MEN1 (0.47) KMT2AMIFMEN1MAPTALDH1A1
SCHEMBL12556215 0.84 MEN1 (0.47) KMT2AMIFMEN1MAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4121421-B1 BIARYL DERIVATIVES AS YAP/TAZ-TEAD PROTEIN-PROTEIN INTERACTION INHIBITORS NOVARTIS AG (CH) 2026-03-11 — — EP disclosed
CN-119241481-A Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors 诺华股份有限公司 2025-01-03 — — CN disclosed
US-20240382457-A1 BIARYL DERIVATIVES AS YAP/TAZ-TEAD PROTEIN-PROTEIN INTERACTION INHIBITORS NOVARTIS PHARMA AG (CH) 2024-11-21 — — US disclosed
CN-115298170-B Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors 诺华股份有限公司 2024-09-27 — — CN disclosed
US-12083101-B2 Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors NOVARTIS AG (CH) 2024-09-10 — — US disclosed
EP-4121421-A1 BIARYL DERIVATIVES AS YAP/TAZ-TEAD PROTEIN-PROTEIN INTERACTION INHIBITORS Novartis AG (CH) 2023-01-25 — — EP disclosed
CN-115298170-A Biaryl derivatives as inhibitors of YAP/TAZ-TEAD protein-protein interactions 诺华股份有限公司 2022-11-04 — — CN disclosed
US-20200261421-A1 HETEROCYCLIC COMPOUNDS AS HIV PROTEASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2020-08-20 — — US disclosed
US-10696639-B2 Heterocyclic compounds as HIV protease inhibitors MERCK SHARP & DOHME CORP. (US) 2020-06-30 — — US disclosed
US-20200069691-A1 HETEROCYCLIC COMPOUNDS AS HIV PROTEASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2020-03-05 — — US disclosed
WO-2018118829-A1 HETEROCYCLIC COMPOUNDS AS HIV PROTEASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2018-06-28 — — WO disclosed
WO-2018106519-A1 HETEROCYCLIC COMPOUNDS AS HIV PROTEASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2018-06-14 — — WO disclosed
US-7786163-B2 Constrained cyano compounds Forest Laboratories Holdings Limited (BM) 2010-08-31 — — US disclosed
EP-1778220-A1 CONSTRAINED CYANO COMPOUNDS Phenomix Corporation (US) 2007-05-02 — — EP disclosed
WO-2006017292-A1 CONSTRAINED CYANO COMPOUNDS PHENOMIX CORPORATION (US) 2006-02-16 — — WO disclosed
US-20060009518-A1 Constrained cyano compounds Forest Laboratories Holding Limited (BM) 2006-01-12 — — US disclosed
US-5164386-A Gastrointestinal and respiratory disorders ISTITUTO DE ANGELI S.P.A. (IT) 1992-11-17 — — US disclosed
EP-0035743-B1 PROCESS FOR THE PREPARATION OF DIPEPTIDES SAGAMI CHEMICAL RESEARCH CENTER (JP) 1984-11-07 — — EP disclosed
US-4352752-A Process for the preparation of dipeptides SAGAMI CHEMICAL RESEARCH CENTER (JP) 1982-10-05 — — US disclosed
EP-0035743-A1 Process for the preparation of dipeptides SAGAMI CHEMICAL RESEARCH CENTER (JP) 1981-09-16 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10696639-B2 Heterocyclic compounds as HIV protease inhibitors PREP, SERPINB1, PEPD KMT2A 2200/4885MIF 569/4885MEN1 4490/4885
US-20060009518-A1 Constrained cyano compounds DNPEP, PREP, PEPD KMT2A 2381/4885MIF 493/4885MEN1 3987/4885
US-12083101-B2 Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors YAP1, TEAD3, TEAD2 KMT2A 1716/4885MIF 2137/4885MEN1 3953/4885
US-20240382457-A1 BIARYL DERIVATIVES AS YAP/TAZ-TEAD PROTEIN-PROTEIN INTERACTION INHIBITORS YAP1, TEAD3, TEAD2 KMT2A 1716/4885MIF 2137/4885MEN1 3953/4885
US-20200261421-A1 HETEROCYCLIC COMPOUNDS AS HIV PROTEASE INHIBITORS PREP, SERPINB1, PEPD KMT2A 2246/4885MIF 591/4885MEN1 4478/4885
US-20200069691-A1 HETEROCYCLIC COMPOUNDS AS HIV PROTEASE INHIBITORS SERPINB1, PREP, PEPD KMT2A 2316/4885MIF 540/4885MEN1 4537/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.